Blog
-
ReadUse light-scattering techniques to predict how your early development candidates will behave at high concentrations for the clinic
Self-association, or the tendency for a molecule to be attracted to itself, is an important assessment criterium for those concerned about how their biologic will behave in the clinic. Researchers...
-
ReadWhat to consider when adding DLS to your early biologics development workflow (FAQs and practical tips)
Dynamic Light Scattering (DLS) is a versatile and simple tool used for assessing the colloidal stability of drug candidates early in protein-based therapeutic development. Like any tool or...
-
ReadHow early discovery and development teams use Dynamic Light Scattering to de-risk downstream biologics development
As a discovery or early development scientist, you’re tasked with identifying the most promising biologics candidates. Your hard work during early development enables straightforward and efficient...
-
Read8 Targeted Protein Degradation conferences in 2023 you won’t want to miss
2023 is expected to be a year of big announcements in the targeted protein degradation (TPD) therapeutics space. With more than 20 degraders in clinical trials, many decisions are coming. The race...
-
Read8 biologics conferences you won’t want to miss in 2023
When you’re part of an industry that moves quickly, it’s important to keep up. You hear about biotherapeutics approvals, and big pharma news, but nothing matches the biologics conference experience.
-
ReadNanoTemper announces Monolith X with breakthrough Spectral Shift technology, enabling affinity measurements where other methods fail
NanoTemper Technologies introduced Monolith X, adding breakthrough Spectral Shift technology to their top-selling Monolith product line.
-
Read5 benefits of optimizing your formulation buffer to get your AAV therapeutic approved
As a gene therapy scientist, you face an abundance of challenges when working to build an effective AAV therapeutic. Many steps of the development workflow have yet to be standardized and the...
-
ReadNanoTemper Technologies welcomes Andreas Schmitz as its first Chief Human Resources Officer
MUNICH, Germany, 18 May 2022 — NanoTemper Technologies, well-known for creating biophysical tools that tackle challenging characterizations, welcomes Andreas Schmitz as the first Chief Human...
-
Read9 Targeted Protein Degradation conferences you don’t want to miss in 2022
Update: See which 2023 conferences you should watch for With so much interest and investment in target protein degradation, a lot can happen in a year. Here are 9 conferences to get up-to-date on...
- Contact Specialist
-
Read8 Gene Therapy conferences you should attend in 2022
With the first AAV-based gene therapies approved, and new gene editing strategies emerging, it’s important to stay on top of the latest topics in this therapeutic area. Here are 8 gene therapy...
-
Read10 terms to help you more easily understand targeted protein degradation
Targeted Protein Degradation (TPD), a relatively new therapeutic approach, is making waves by targeting otherwise ‘undruggable’ proteins. PROTACs are the best-understood protein degraders, with...
-
ReadNanoTemper Technologies launches Spectral Shift, a breakthrough technology that changes the game for affinity-based screenings
NanoTemper Technologies, announced today the launch of Spectral Shift technology within their Dianthus instrument, built to handle the most challenging affinity-based screenings in drug discovery....
-
ReadNanoTemper Technologies arms gene therapy scientists with Static Light Scattering to sharpen their tool kit for development of AAVs
SOUTH SAN FRANCISCO, Calif Feb 16 2022 — NanoTemper Technologies today announced the addition of Static Light Scattering (SLS) to their wildly successful Prometheus Panta, turning their instrument...
-
Read
How do you get reproducible data from protein characterization experiments? Try following this DIN SPEC
Reproducibility is a key tenet of scientific research, but many pharma groups have projects that collaborate across different sites or that rely on materials prepared by other specialist...
-
ReadFor protein degraders to tackle neurodegenerative diseases, these are the barriers they need to overcome
Neurodegenerative diseases (ND) and cancer are the two major targets in the pipelines of companies focused on targeted protein degradation as a therapeutic modality. Proteins involved in NDs —...
-
ReadWhy so many companies are betting on PROTACs as a superior therapeutic modality
With PROTACs currently in the clinical and preclinical stages, they are making exciting progress towards successfully treating patients who have been waiting for effective therapies for certain...
-
Read5 formulation changes you can evaluate with Dynamic Light Scattering to increase your biologics candidates’ success
Biologics researchers are deeply concerned with formulation. Formulation typically refers to the final development of a deliverable, biologically derived molecule (such as a protein, peptide,...
-
ReadNanoTemper gets Top 100 award as one of Germany’s most innovative SMEs in 2021
NanoTemper has been given this year’s TOP 100 seal, an award that honors innovative German small and medium-sized companies. The TOP 100 innovation competition is organized by compamedia, and...
-
ReadNanoTemper’s Monolith wins top global design award: Red Dot Award
NanoTemper’s newest Monolith instrument has been awarded the Red Dot Award, an internationally recognized seal of excellence in design. Both bold aesthetics and user-friendly design have always...
-
ReadNanoTemper launches Andromeda, helping Biopharma and CROs to increase efficiency of expression screening for membrane proteins
SOUTH SAN FRANCISCO, Calif. June 24, 2021 — NanoTemper Technologies, well-known for creating biophysical tools that tackle challenging characterizations, enters the protein production market with...
-
Loading more...
